{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:23:40Z","timestamp":1778520220260,"version":"3.51.4"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023674","name":"Deanship of Scientific Research, King Khalid University","doi-asserted-by":"publisher","award":["RGP2\/11\/46"],"award-info":[{"award-number":["RGP2\/11\/46"]}],"id":[{"id":"10.13039\/501100023674","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>This study aimed to examine prescribing trends for Parkinson\u2019s disease (PD) medications in the United Kingdom from 2019 to 2024, focusing on the impact of guidelines from the American Academy of Neurology (AAN) and the National Institute for Health and Care Excellence (NICE) on the use of levodopa and dopamine agonists (DAs). A repeated cross-sectional design was employed, using publicly available data to assess prescribing patterns across the four UK countries. An interrupted time series analysis with linear regression was performed to identify trends, comparing regions with England as the reference point. Levodopa remained the most prescribed PD medication across all UK regions, as revealed by the analysis. In England, levodopa prescriptions increased significantly after the introduction of AAN guidelines, while other regions displayed more stable trends. Northern Ireland exhibited a distinct pattern, with DAs prescribed more frequently than levodopa. The findings also indicated that Scotland and Wales were less responsive to AAN guidance. This study highlights the influence of clinical guidelines on PD prescribing practices in the UK, with regional variations suggesting possible demographic or healthcare system factors. Further research is required to understand these disparities and their implications for PD management.<\/jats:p>","DOI":"10.1371\/journal.pone.0324999","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T18:06:14Z","timestamp":1748023574000},"page":"e0324999","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Trends in Parkinson\u2019s disease medication prescribing patterns in the UK: An interrupted time series analysis (2019\u20132024)"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-2306","authenticated-orcid":true,"given":"Khalid","family":"Orayj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"10291","key":"pone.0324999.ref001","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"BR Bloem","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"pone.0324999.ref002","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","article-title":"Epidemiology of Parkinson disease","volume":"34","author":"A Lee","year":"2016","journal-title":"Neurol Clin"},{"issue":"1","key":"pone.0324999.ref003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41531-022-00284-0","article-title":"Change in the incidence of Parkinson\u2019s disease in a large UK primary care database","volume":"8","author":"O Okunoye","year":"2022","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"pone.0324999.ref004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/jech.2008.084954","article-title":"Socioeconomic variations in the prevalence and incidence of Parkinson\u2019s disease: a population-based analysis","volume":"64","author":"LM Lix","year":"2010","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"pone.0324999.ref005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1212\/WNL.57.3.462","article-title":"Time trends in the incidence of parkinsonism in Olmsted county, Minnesota","volume":"57","author":"WA Rocca","year":"2001","journal-title":"Neurology"},{"key":"pone.0324999.ref006","doi-asserted-by":"crossref","first-page":"107015","DOI":"10.1016\/j.parkreldis.2024.107015","article-title":"No trend to rising rates: a review of Parkinson\u2019s prevalence studies in the United Kingdom","volume":"128","author":"R Varden","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"pone.0324999.ref007","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1212\/01.wnl.0000206363.57955.1b","article-title":"Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology","volume":"66","author":"O Suchowersky","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"pone.0324999.ref008","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2174\/1570159X14666151208114634","article-title":"Revisiting the medical management of Parkinson\u2019s disease: levodopa versus dopamine agonist","volume":"14","author":"J Zhang","year":"2016","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"pone.0324999.ref009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.59.8.1292","article-title":"Practice parameter: initiation of treatment for Parkinson\u2019s disease: an evidence-based review","volume":"59","author":"R Inzelberg","year":"2002","journal-title":"Neurology"},{"issue":"9949","key":"pone.0324999.ref010","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial","volume":"384","author":"PD Med Collaborative Group","year":"2014","journal-title":"Lancet"},{"key":"pone.0324999.ref011","volume-title":"Parkinson\u2019s disease in adults: diagnosis and management","year":"2017"},{"issue":"11","key":"pone.0324999.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225723","article-title":"The characteristics and treatment patterns of patients with Parkinson\u2019s disease in the United States and United Kingdom: a retrospective cohort study","volume":"14","author":"L Kalilani","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"pone.0324999.ref013","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jsps.2021.01.004","article-title":"Factors affecting the choice of first-line therapy in Parkinson\u2019s disease patients in Wales: a population-based study","volume":"29","author":"K Orayj","year":"2021","journal-title":"Saudi Pharm J"},{"issue":"20","key":"pone.0324999.ref014","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","article-title":"Dopaminergic therapy for motor symptoms in early parkinson disease practice guideline summary: a report of the AAN guideline subcommittee","volume":"97","author":"T Pringsheim","year":"2021","journal-title":"Neurology"},{"key":"pone.0324999.ref015","year":"2024"},{"key":"pone.0324999.ref016","author":"NHS Wales Shared Services Partnership","year":"2024"},{"key":"pone.0324999.ref017","article-title":"Monthly prescribing activity data.","author":"Public Health Scotland","year":"2024"},{"key":"pone.0324999.ref018","author":"OpenData NI","year":"2024"},{"key":"pone.0324999.ref019","volume-title":"Pharmacotherapeutic interventions in Parkinson\u2019s disease: investigating prescribing factors and health outcomes","author":"K Orayj","year":"2020"},{"key":"pone.0324999.ref020","author":"Office for National Statistics","year":"2024"},{"issue":"5","key":"pone.0324999.ref021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","author":"RM O\u2019brien","year":"2007","journal-title":"Qual Quant"},{"issue":"4","key":"pone.0324999.ref022","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2307\/2297285","article-title":"Serial Correlation and the Fixed Effects Model","volume":"49","author":"A Bhargava","year":"1982","journal-title":"Rev Econ Stud"},{"issue":"6","key":"pone.0324999.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099021","article-title":"Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010","volume":"9","author":"S Nakaoka","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"pone.0324999.ref024","article-title":"Initial medication in patients of newly diagnosed Parkinson\u2019s disease in Taiwan","volume":"9","author":"Y-J Guo","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"pone.0324999.ref025","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1212\/01.wnl.0000210433.49727.40","article-title":"Initial pharmacotherapy in a population of veterans with Parkinson disease","volume":"66","author":"K Swarztrauber","year":"2006","journal-title":"Neurology"},{"key":"pone.0324999.ref026","first-page":"9237181","article-title":"Patterns and determinants of prescribing for Parkinson\u2019s Disease: a systematic literature review","volume":"2019","author":"K Orayj","year":"2019","journal-title":"Parkinsons Dis"},{"issue":"2","key":"pone.0324999.ref027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0891988706286512","article-title":"Patterns of initial pharmacotherapy for Parkinson\u2019s disease in the United States","volume":"19","author":"DM Huse","year":"2006","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"pone.0324999.ref028","doi-asserted-by":"crossref","DOI":"10.1136\/JNNP-2023-ABN.284","article-title":"Acute neurological admissions in Northern Ireland: amount, hospital type and admission specialty using GIRFT methodology.","volume-title":"Association of British neurologists: annual meeting abstracts 2023","author":"M Ferghal","year":"2023"},{"issue":"9","key":"pone.0324999.ref029","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/mds.28623","article-title":"Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in early Parkinson\u2019s disease","volume":"36","author":"E McIntosh","year":"2021","journal-title":"Mov Disord"},{"issue":"9","key":"pone.0324999.ref030","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11316770-000000000-00000","article-title":"Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson\u2019s disease in the UK setting: an economic Markov model evaluation","volume":"26","author":"A Haycox","year":"2009","journal-title":"Drugs Aging"},{"issue":"6","key":"pone.0324999.ref031","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/09540962.2014.962367","article-title":"Resource allocation in the Northern Ireland health service: consensus or challenge?","volume":"34","author":"P McGregor","year":"2014","journal-title":"Public Money & Management"},{"issue":"3","key":"pone.0324999.ref032","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208028","article-title":"Patient with parkinson disease and care partner perceptions of key domains affecting health-related quality of life: systematic review","volume":"102","author":"MH Tosin","year":"2024","journal-title":"Neurology"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T18:06:23Z","timestamp":1748023583000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324999"}},"subtitle":[],"editor":[{"given":"Saira Saeed","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324999","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}